| Model Number: | CAS: 571190-30-2 |
|---|---|
| Brand Name: | NJBN |
| Grade Standard: | |
| Type: | |
| Place of Origin: | China (Mainland) |
| MF: | C24H29N7O2 |
| Other Names: | Palbociclib |
| CAS No.: | 571190-30-2 |
Quick Details
Specifications
Pharmaceutical Raw Materials CAS 571190-30-2 Palbociclib
Quick Detail:
Product Description:
1. Palbociclib is used in combination with (Femara) to treat a certain type of hormone receptor-positive, advanced breast cancer (breast cancer that depends on hormones such as estrogen to grow) in women who have experienced menopause (change of life; end of monthly menstrual periods). Palbociclib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells.
2. A new drug for the treatment of breast cancer with a novel mechanism of action, palbociclib (Ibrance) has been granted accelerated approval by the US Food and Drug Administration (FDA), two months ahead of schedule.Palbociclib is indicated for use with the aromatase inhibitor as first-line treatment in postmenopausal women with metastatic breast cancer that is estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative.The new drug acts as an inhibitor of cyclin-dependent kinases 4 and 6, which are involved in promoting the growth of cancer cells, the FDA noted.
"The addition of palbociclib to provides a novel treatment option to women diagnosed with metastatic breast cancer," said Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.
3. The agency granted the drug breakthrough therapy designation because the sponsor demonstrated through preliminary clinical evidence that the drug may offer a substantial improvement over available therapies, the FDA said. It also received priority review, which provides for expedited review of drugs intended to provide a significant improvement in safety or effectiveness in the treatment of a serious condition or meet an unmet medical need.
Application:
Palbociclib is approved to be used with other drugs to treat:Breast cancer that is hormonereceptor positive (HR+) and HER2 negative(HER2-) and is advanced or has metastasized (spread to other parts of the body).It is used with in women whose disease has gotten worse after treatment with hormone therapy.It is used with letrozole in postmenopausal women who have not been treated with hormone therapy.Palbociclib is also being studied in the treatment of other types of cancer.
Quick Detail:
Product Description:
1. Palbociclib is used in combination with (Femara) to treat a certain type of hormone receptor-positive, advanced breast cancer (breast cancer that depends on hormones such as estrogen to grow) in women who have experienced menopause (change of life; end of monthly menstrual periods). Palbociclib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells.
2. A new drug for the treatment of breast cancer with a novel mechanism of action, palbociclib (Ibrance) has been granted accelerated approval by the US Food and Drug Administration (FDA), two months ahead of schedule.Palbociclib is indicated for use with the aromatase inhibitor as first-line treatment in postmenopausal women with metastatic breast cancer that is estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative.The new drug acts as an inhibitor of cyclin-dependent kinases 4 and 6, which are involved in promoting the growth of cancer cells, the FDA noted.
"The addition of palbociclib to provides a novel treatment option to women diagnosed with metastatic breast cancer," said Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.
3. The agency granted the drug breakthrough therapy designation because the sponsor demonstrated through preliminary clinical evidence that the drug may offer a substantial improvement over available therapies, the FDA said. It also received priority review, which provides for expedited review of drugs intended to provide a significant improvement in safety or effectiveness in the treatment of a serious condition or meet an unmet medical need.
Application:
Palbociclib is approved to be used with other drugs to treat:Breast cancer that is hormonereceptor positive (HR+) and HER2 negative(HER2-) and is advanced or has metastasized (spread to other parts of the body).It is used with in women whose disease has gotten worse after treatment with hormone therapy.It is used with letrozole in postmenopausal women who have not been treated with hormone therapy.Palbociclib is also being studied in the treatment of other types of cancer.
Payment & Delivery Information:
Payment Method: Western Union, Money Gram, T / T, Bitcoin
Minimum order: 10-100 grams. Our min packing of each powder is 10g or 100g, but some expensivepowder can be bought at several grams. As for oil steroids, our MOQ is 50ml.
Professional Delivery: By courier (EMS, DHL, Fedex, UPS, TNT) is preferrable, bulk order can benegotiable.
Dispatch time: As for powders, within 24h once the receipt of payment. As for oil liquid, within 48h once the receipt of payment.
Tracking number: Can be offered to you within 48h for powders. Could be provided to you within 72h for oil liquid.
Delivery time: 4 ~ 6 working days after the receipt of payment for powders by courier, 5 ~ 7 working days after the receipt of payment for oil liquid by courier.
Discreetly Packing: Safe and professional disguised package can be guaranteed. We also have completely re-send policy to some areas. As for most countries, we will resend your parcel if your parcel fail to pass customs.
Adequate Stock: Most of powders are in stock. We export over 1000 kilograms of steroid powder per month.
High Delivery Rate: Our goods packing will not contain any hormone information and can be sent out from different areas of china. At present, the goods customs clearance rate rate we send to United states and Europe is 99%, As for Canada, Brazil of quite High buckle close rate area, we also have a new way to pass the customs.